Nanjing is sunny " meth sulfonate shamphetamine tablets" debuted on the market

On December 3rd, CDE's official website showed that the listing of the class 3 generic drug "Methosulphate Shamphamine Tablets" in Nanjing was accepted.
the drug is a Parkinson's disease treatment drug, there are no other enterprises in the country to declare.
, or sacpenamine, is a highly selective and reversible third-generation monoamine oxidase B (MAO-B) inhibitor with both dopamine and non-dopamine energy mechanisms.
On the one hand, the drug reduces the degradation of dopamine that has been secreted and helps maintain dopamine concentrations in the brain, and on the other hand, it blocks the flow of voltage-dependent sodium ions on neurons, thereby inhibiting the release of glutamate.
is by far the most effective and widely used drug for Parkinson's, with up to 75% of patients taking the drug.
, but as the disease progresses, the duration of the effect of L-Doba (ON-Time) decreases gradually, with the so-called "wearing-off" phenomenon.
is developed by Italy's Zambon and Newron.
On March 22, 2017, safinamide was approved by the FDA for listing, becoming the first new chemical entity (NCE) approved in the United States in more than 10 years for the treatment of Parkinson's disease, an auxiliary treatment for Parkinson's patients with OFF phenomena to extend the efficacy of lychee dopa, a product called Xadago.
The Insight database shows that only Nanjing is now sunny sacinamide first reported for listing.
3 companies are in clinical trials, including Yangzijiang Pharmaceuticals and Ruiyang Pharmaceuticals, which have initiated BE trials, and Hainan Zanbang Pharmaceuticals, which is in Phase III clinical trials, and 3 companies, including Stone Pharmaceuticals Group, which have been approved for clinical trials.
。